Cure8 news brief
This press release signals a step toward a new local, regenerative approach for treating complex perianal fistulas—a difficult Crohn’s complication with limited options. If clinical trials proceed, the therapy could add to future treatment choices.
Patients with complex perianal fistulas, gastroenterologists and colorectal surgeons, clinical researchers in regenerative therapies, and patient advocates following emerging Crohn’s treatments.
EVerGel™ combines mesenchymal stem cell–derived exosomes with a biocompatible hydrogel intended to keep the product at the fistula site and promote tissue healing. The company reports favorable safety and biodistribution results in two animal species and is preparing a CTA (clinical trial application) to seek regulatory approval for a first-in-human study.
Clinical context and next steps: These are nonclinical (preclinical) results only; clinical studies will be required to test safety and any therapeutic benefit in patients. The company aims to file its CTA and, if approved, begin first-in-human administration by the end of the first half of 2027.
Press materials note ongoing partner discussions and further pipeline work.
The source is a company press release reporting preclinical results and development plans. Preclinical safety and biodistribution in animals do not predict human outcomes; regulatory review and clinical trials are still required. No clinical efficacy or human safety data are presented in this release.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.
Perianal fistulas are a serious, hard-to-treat complication of Crohn disease. Fast Track status may speed development of a new implantable stem cell therapy that aims to close fistulas and promote local healing. Ongoing...
Fistulizing Crohn’s disease is a major complication where durable structural repair is hard to achieve. Regenerative cell-sheet approaches aim to rebuild tissue architecture rather than only suppress inflammation, which...
